Legal & General Group PLC Ovid Therapeutics Inc. Transaction History

Legal & General Group PLC

$470 Billion
Q3 2024

A detailed history of Legal & General Group PLC transactions in Ovid Therapeutics Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 6,579 shares of OVID stock, worth $6,973. This represents 0.0% of its overall portfolio holdings.

Number of Shares

6,579

Previous 6,579 -0.0%

Holding current value

$6,973

Previous $7,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$0.7 - $3.34 $964 - $4,602	1,378 Added 26.49%	6,579 $5,000
Q4 2023 Feb 15, 2024	BUY	$2.98 - $3.78 $1,752 - $2,222	588 Added 12.75%	5,201 $16,000
Q3 2023 Nov 14, 2023	SELL	$3.23 - $3.97 $3,714 - $4,565	-1,150 Reduced 19.95%	4,613 $17,000
Q2 2023 Aug 14, 2023	BUY	$2.53 - $3.89 $14,580 - $22,418	5,763 New	5,763 $18,000
Q2 2021 Aug 12, 2021	SELL	$3.3 - $4.49 $17,156 - $23,343	-5,199 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$2.42 - $4.47 $51,599 - $95,309	-21,322 Reduced 80.4%	5,199 $21,000
Q4 2020 Feb 12, 2021	BUY	$2.28 - $6.84 $48,614 - $145,842	21,322 Added 410.12%	26,521 $61,000
Q3 2020 Nov 13, 2020	SELL	$5.39 - $8.24 $10,041 - $15,351	-1,863 Reduced 26.38%	5,199 $30,000
Q2 2020 Aug 14, 2020	BUY	$2.67 - $7.91 $18,855 - $55,860	7,062 New	7,062 $52,000
Q3 2019 Nov 13, 2019	SELL	$1.76 - $3.51 $3,775 - $7,528	-2,145 Closed	0 $0
Q1 2018 May 17, 2018	BUY	$6.53 - $9.82 $6,836 - $10,281	1,047 Added 95.36%	2,145 $15,000
Q4 2017 Feb 13, 2018	BUY	$6.12 - $12.31 $6,719 - $13,516	1,098	1,098 $11,000

Others Institutions Holding OVID

# of Institutions

Shares Held

39M

Call Options Held

37.4K

Put Options Held

500

View Full List

About Ovid Therapeutics Inc.

Ticker OVID
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,419,400
Market Cap $74.6M
Description
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment o...

More about OVID

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.

Account

Legal & General Group PLC Ovid Therapeutics Inc. Transaction History